Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Receives Notification of Nasdaq Non-Compliance

NEW YORK (GenomeWeb) – Rosetta Genomics said today that it has received notification from the Nasdaq that it no longer meets the exchange's stockholder equity listing requirement.

According to Rosetta, it has received a letter from the Nasdaq indicating that it is not in compliance with a listing rule requiring a minimum of $2.5 million in stockholders' equity. The company said it has 45 days from Oct. 24 to submit a specific plan to regain compliance with this requirement. If the plan is accepted, the Nasdaq may provide Rosetta with up to 180 calendar days from the date of the notification to regain compliance.

Earlier this year, Rosetta effected a 1-for-12 reverse stock split after failing to meet the Nasdaq's $1 minimum bid price requirement.

During early morning trading, shares of Rosetta were up $.01 at $.80.


The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.